NAFDAC Blacklists Ayrtons Saunders Ltd for Import Breaches

• NAFDAC has officially blacklisted UK-based pharmaceutical manufacturer Ayrtons Saunders Ltd following investigations into regulatory violations.
• Products manufactured by the UK firm were imported and marketed in Nigeria through local distributor Mofus Nig. Ltd.
• The regulatory agency issued a public notice banning all entry, sale, and distribution of Ayrtons Saunders Ltd products across the country.
• Importers, distributors, and healthcare providers must audit inventory immediately to isolate affected stock and avoid regulatory enforcement.

Consequently, legal counsel for pharmaceutical importers, distributors, and healthcare facilities must immediately audit inventory and supply chains to quarantine any products manufactured by Ayrtons Saunders Ltd or supplied by Mofus Nig. Ltd to prevent regulatory sanctions and product seizures by NAFDAC.

Nigeria's chief drug regulatory authority, the National Agency for Food and Drug Administration and Control (NAFDAC), has formally announced that NAFDAC blacklists Ayrtons Saunders Ltd following investigations into regulatory infractions. The regulatory body issued a public notice confirming that the sanction stems from documented non-compliance and Nigeria pharmaceutical importation regulatory violations discovered during official inquiries into the company's supply operations.

According to the enforcement directive, Ayrtons Saunders Ltd operated in the Nigerian market through its local marketing representative, Mofus Nig. Ltd. The official NAFDAC drug importation enforcement notice serves as a direct alert to the general public, medical institutions, commercial distributors, and industry stakeholders regarding the prohibition of products linked to the British firm.

The decision to blacklist Ayrtons Saunders Ltd highlights NAFDAC's intensified monitoring of foreign manufacturing entities and their domestic trade partners. Investigators identified procedural breaches surrounding the importation and distribution pathways established by Mofus Nig. Ltd, prompting the immediate revocation of regulatory approvals for products manufactured by the UK entity.

By placing Ayrtons Saunders Ltd on the administrative ban list, NAFDAC has effectively halted all legal entry, clearance, and sale of the firm's medicinal products within Nigerian borders. Healthcare establishments and supply chain operators have been instructed to monitor their procurement channels to ensure strict adherence to the agency's regulatory directive.

This enforcement action underscores the critical risks facing domestic healthcare providers and logistics partners when foreign suppliers commit regulatory breaches. As NAFDAC blacklisted foreign pharmaceutical companies face stringent enforcement, domestic distributors and clinical entities bear a heightened burden to verify the regulatory standing of their offshore partners and local marketing agents.

Corporate legal teams and compliance officers operating within the pharmaceutical sector must closely observe actions concerning Ayrtons Saunders Mofus Nig Ltd NAFDAC interactions to mitigate regulatory exposure. When the authority blacklists a foreign manufacturer alongside its local representative, downstream businesses face severe legal exposure if banned stocks remain within commercial distribution networks.

Consequently, legal counsel for pharmaceutical importers, distributors, and healthcare facilities must immediately audit inventory and supply chains to quarantine any products manufactured by Ayrtons Saunders Ltd or supplied by Mofus Nig. Ltd to prevent regulatory sanctions and product seizures by NAFDAC. Compliance teams are urged to implement rigorous internal controls to isolate affected stocks and maintain continuous compliance with national drug regulations.

Compliance officers and legal counsel for pharmaceutical importers, distributors, and healthcare facilities must immediately audit inventory and supply chains to quarantine any products manufactured by Ayrtons Saunders Ltd or supplied by Mofus Nig. Ltd to prevent regulatory sanctions and product seizures by NAFDAC.

Source: Original reporting via NAFDAC official public notice.